Why Did Oppenheimer Upgrade Prothena’s Stock?

In a report released today, Jay Olson from Oppenheimer upgraded Prothena (PRTAResearch Report) to Buy, with a price target of $16.00. The company’s shares closed last Wednesday at $10.92.

According to TipRanks.com, Olson has 0 stars on 0-5 stars ranking scale with an average return of -6.7% and a 41.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.

Prothena has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.63 and a one-year low of $6.71. Currently, Prothena has an average volume of 288.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.